Skip to main content
Article thumbnail
Location of Repository

Optimizing combination treatment in the management of type 2 diabetes

By Giuseppe Derosa and Salvadeo Sibilla


Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often fails after a period of treatment, so that multiple drugs are needed to achieve effective glycemic control. A number of oral glucose lowering drugs is now available such as metformin, sulfonylureas, non-sulfonylureas secretagogues (metiglinides derivatives), alpha-glucosidases inhibitors, and the newest agent: thiazolidinediones (TZD). The possible associations of oral glucose lowering drugs for optimal treatment of type 2 diabetes are briefly reviewed. In particular, the effects of different classes of drugs on cardiovascular risk factors (and particular hypertension and dyslipidemia) and well recognized cardiovascular disease markers in type 2 diabetes are analyzed: in this context TZD appear the more innovative drugs and have been shown to play a key role in the management of hypertension, dyslipidemia, inflammation and endothelial disfunction in diabetic patients. The possible adverse effects derived from the association of different drug classes are also considered

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2004). A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Clin Ther,
    2. (2005). A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract,
    3. (2005). Antithrombotic effects of rosiglitazone-metfromin vs glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome).
    4. (2004). Clinical interest of PPARs ligands.
    5. (2004). Consensus Statement Thiazolidinedione Use, fl uid retention and congestive heart failure. Diabetes Care,
    6. (2003). Diabetes control with physical activity and exercise. Nutr Clin Care,
    7. (2003). Effect of thiazolidinediones on body weight in patients with type 2 diabetes mellitus.
    8. (2004). Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.
    9. (2004). Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
    10. (2006). Effects of rosiglitazone on lipids, adipokines, and infl ammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
    11. (2006). Exercise and diabetes.
    12. (2004). Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care,
    13. (2006). Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract,
    14. (2006). Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    15. (2006). Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract,
    16. (2005). Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab,
    17. (2005). Long-term effects of glimepiride and rosiglitazone on non-conventionall cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomised, double-blind clinical trial.
    18. (2005). Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther,
    19. (2006). Management of cardiovascular risk factors in people with diabetes in primary care: Cross-sectional study. Public Health,
    20. (2007). Metabolic effect of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
    21. (2003). Metformin: new understandings, new uses.
    22. (2004). One-year glycemic control with a sulphonylurea plus pioglitazone versus a sulphonylurea plus metformin in patients with type 2 diabetes. Diabetes Care,
    23. (2005). Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    24. (2002). Oral antihyperglycemic therapy for type 2 diabetes: scientifi c review.
    25. (2006). Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endotheliumdependent dilation in nondiabetic patients with major cardiovascular risk factors.
    26. (2003). Peroxisome proliferatoractivated receptors-γ agonists in atherosclerosis: current evidence and future directions. Curr Opinion Lipidol,
    27. (2004). Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol,
    28. (1994). Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care,
    29. (2006). Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
    30. (2004). Rosiglitazone plus metformin combination effects on cardiovasula risk markers suggest potential cardiovascular benefi ts in type 2 diabetic patients (abstract n.121–OR) Diabetes, Suppl 2:28.
    31. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial macroVascular Events): a randomised control trial.
    32. (2006). Standards in medical care in diabetes. Diabetes Care,
    33. (2003). Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab,
    34. (2005). The clinical signifi cance of PPAR gamma agonism. Current molecular medicine,
    35. (2004). The role of sulphonylureas in the management of type diabetes mellitus.
    36. (2003). Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract,
    37. (2005). Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.
    38. (2005). Type 2 diabetes as an infl ammatory cardiovascular disorder.
    39. (1999). Vascular Health and Risk Management 2007:3(5) 671 Combination treatment for type 2 diabetes

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.